Analysts Set Lucid Diagnostics Inc. (NASDAQ:LUCD) PT at $3.65

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $3.65.

A number of equities research analysts recently weighed in on LUCD shares. Wall Street Zen raised shares of Lucid Diagnostics from a “sell” rating to a “hold” rating in a research note on Sunday, September 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research note on Wednesday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Saturday, September 27th. Finally, BTIG Research raised their target price on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a research note on Friday, September 5th.

Insiders Place Their Bets

In related news, Director Dennis Matheis bought 100,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were acquired at an average cost of $1.02 per share, with a total value of $102,000.00. Following the completion of the purchase, the director directly owned 665,443 shares of the company’s stock, valued at $678,751.86. This trade represents a 17.69% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 6.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Berkshire Asset Management LLC PA bought a new position in Lucid Diagnostics during the first quarter valued at approximately $30,000. Northwestern Mutual Wealth Management Co. bought a new position in Lucid Diagnostics during the first quarter valued at approximately $37,000. Quadrature Capital Ltd bought a new position in Lucid Diagnostics during the second quarter valued at approximately $29,000. Cubist Systematic Strategies LLC bought a new position in Lucid Diagnostics during the first quarter valued at approximately $39,000. Finally, Traphagen Investment Advisors LLC bought a new position in Lucid Diagnostics during the second quarter valued at approximately $34,000. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Stock Up 2.0%

Shares of LUCD opened at $1.04 on Tuesday. The business’s 50-day moving average price is $1.09 and its 200-day moving average price is $1.22. Lucid Diagnostics has a twelve month low of $0.75 and a twelve month high of $1.80. The stock has a market cap of $138.82 million, a PE ratio of -0.87 and a beta of 1.19.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.